Severe infliximab-induced psoriasis treated with adalimumab switching.
Antitumor necrosis factor (anti-TNF) agents are a well-established treatment for various medical conditions, including psoriasis and psoriatic arthritis. However, anti-TNF agents may themselves induce psoriasis in some patients. The authors report two cases of patients with severe and refractory infliximab-induced psoriasis. The patients had good clinical responses after switching to another TNF blocker. For severe cases, infliximab withdrawal combined with conventional immunosuppressive psoriasis drugs or with adalimumab may be a therapeutic option.